接受维持化疗的急性淋巴细胞白血病患儿继发性低丙种球蛋白血症的影响
本研究回顾性分析85例完成TPOG-ALL-2013维持治疗的儿童急性淋巴细胞白血病患者,诊断时低丙种球蛋白血症占6%(5/85),维持化疗期间升至49.2%(32/65)。极高危疾病、不良细胞遗传学或基线IgG<1000 mg/dL者更易发生继发性低丙种球蛋白血症,低丙种球蛋白血症组发热事件更常见(40.6%有>10次发热),但低丙种球蛋白血症与白细胞计数、可测量残留病或长期生存结局无关。
要点
- 维持化疗期间低丙种球蛋白血症患病率升至49.2%(32/65)。
- 极高危、不良细胞遗传学或基线IgG<1000 mg/dL者更易发生继发性低丙种球蛋白血症。
- 低丙种球蛋白血症组发热事件更常见(40.6%有>10次发热),IgG<400 mg/dL者尤其频繁。
核心结论
- 儿童ALL维持化疗期间继发性低丙种球蛋白血症患病率高,且与发热事件相关。
- 低丙种球蛋白血症与白细胞计数、可测量残留病或长期生存结局无关。
- 常规IgG监测可能有助于识别高危患者,但IVIG补充的临床获益尚需进一步研究确定。
研究设计与样本
- 回顾性研究,纳入85例完成台湾儿童肿瘤协作组(TPOG)-ALL-2013维持治疗的儿童ALL患者。
主要发现
- 诊断时低丙种球蛋白血症占6%(5/85),维持化疗期间升至49.2%(32/65)。
- 极高危疾病、不良细胞遗传学或基线IgG<1000 mg/dL的患者更易发生继发性低丙种球蛋白血症。
- 低丙种球蛋白血症组发热事件显著更常见,40.6%有>10次发热,IgG<400 mg/dL者尤其频繁。
- 低丙种球蛋白血症与白细胞计数、可测量残留病或长期生存结局无关。
关键数值与推荐
- 诊断时低丙种球蛋白血症6%(5/85)。
- 维持化疗期间低丙种球蛋白血症49.2%(32/65)。
- 基线IgG<1000 mg/dL者更易发生继发性低丙种球蛋白血症。
- 低丙种球蛋白血症组40.6%有>10次发热事件。
临床怎么用
- 鉴于低丙种球蛋白血症高患病率及其与发热事件的关联,常规IgG监测可能有助于识别高危患者。
- IVIG替代治疗在儿童ALL中的作用尚不确定,需进一步研究确定其临床获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypogammaglobulinaemia is a potential complication in children with acute lymphoblastic leukaemia (ALL) receiving chemotherapy. However, real-world data on its prevalence and clinical impact remain limited. This study retrospectively reviewed 85 paediatric ALL patients completing Taiwan Pediatric Oncology Group (TPOG)-ALL-2013 maintenance therapy to investigate secondary hypogammaglobulinaemia. At diagnosis, 6% (5/85) of patients had hypogammaglobulinaemia, increasing to 49.2% (32/65) during maintenance chemotherapy. Patients with very-high-risk disease, poor cytogenetics or baseline immunoglobulin G (IgG) <1000 mg/dL were more likely to develop secondary hypogammaglobulinaemia. Febrile episodes were significantly more common in the hypogammaglobulinaemia group (40.6% had >10 fever episodes) and were particularly frequent in patients with IgG <400 mg/dL. However, hypogammaglobulinaemia was not associated with white blood cell count, measurable residual disease or long-term survival outcomes. Although intravenous immunoglobulin (IVIG) replacement is well established in primary immunodeficiency and B-cell malignancies, its role in paediatric ALL remains uncertain. Given the high prevalence of hypogammaglobulinaemia and its association with febrile episodes, routine IgG monitoring may help identify at-risk patients. Further studies are needed to determine the clinical benefits of IVIG supplementation in this population.
引用
- Cheng CN, Yang YN, Yeh YH, et al. The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy. Br J Haematol. 2025. PMID: 40685714. doi:10.1111/bjh.70027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。